Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 4,600 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Up 0.7%

KNSA stock opened at $80.47 on Friday. The firm has a 50-day moving average of $71.61 and a two-hundred day moving average of $57.21. Kiniksa Pharmaceuticals International, plc has a 12 month low of $35.06 and a 12 month high of $82.94. The company has a market cap of $6.28 billion, a price-to-earnings ratio of 82.96 and a beta of 0.09.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The business had revenue of $243.60 million for the quarter, compared to analysts’ expectations of $226.49 million. As a group, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current year.

Analysts Set New Price Targets

KNSA has been the subject of a number of recent research reports. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Wedbush boosted their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. upped their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Canaccord Genuity Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Finally, Weiss Ratings cut shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $87.38.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several large investors have recently made changes to their positions in the stock. Rubric Capital Management LP increased its holdings in Kiniksa Pharmaceuticals International by 2.3% in the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after purchasing an additional 90,194 shares during the last quarter. Vanguard Group Inc. lifted its stake in Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after purchasing an additional 49,802 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Kiniksa Pharmaceuticals International by 6,384.0% during the second quarter. California State Teachers Retirement System now owns 2,721,648 shares of the company’s stock worth $174,049,000 after buying an additional 2,679,673 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in shares of Kiniksa Pharmaceuticals International by 45.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after buying an additional 332,846 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.